Jonathan Gardner
Jonathan Gardner covers the business of biopharmaceuticals for BioPharma Dive, with a focus on how scientific advances and clinical data translate into commercial power, especially in cancer. His coverage stands out for treating trial readouts and licensing deals as inflection points that reshape competitive dynamics, rather than as isolated events. He writes in clear, grounded language that connects mechanisms of action, study design and market strategy in the same frame.
Cancer drug pipelines and antibody-drug conjugates
Gardner’s work zeroes in on oncology pipelines, using individual studies to show how new therapies might change standards of care and market share.
In covering Merck’s antibody-drug conjugate licensed from a Chinese partner and tested in a first large global trial, he explains not just that the drug “hits the mark,” but what that means in terms of endpoints, patient populations and the future positioning of the product. His stories stay close to the evidence, unpacking the details of trial design and outcome measures while keeping sight of which competitors, indications and lines of therapy are most at stake.
He treats complex modalities like antibody-drug conjugates as business stories rooted in biology, making clear how attributes such as targeting, safety and delivery shape commercial value.
Cross-border licensing and Chinese biotech partnerships
A recurring thread in Gardner’s beat is the flow of innovative drugs and technologies between Chinese biotechs and global pharmaceutical companies. When he writes about a Merck oncology drug licensed from China, he uses the case to show how cross-border deals are restructuring who controls key assets in hot areas like targeted oncology. He pays attention to which company holds development and commercialization rights in different territories, why a Western pharma company turns to a Chinese partner, and what that implies for timelines, competition and access in major markets.
His coverage highlights licensing as a strategic tool, not just a legal formality, and makes clear how these alliances can alter both regional and global drug landscapes.
Clinical data with clear commercial stakes
Across his business beat, Gardner treats clinical data as the backbone of valuation, dealmaking and portfolio strategy. In writing about pivotal studies, he explains the strength of the evidence, the stage of development and the remaining regulatory hurdles, then ties those factors directly to questions such as market entry, pricing leverage and label expansion. He is attentive to how a “first big global trial” differs from earlier, smaller studies in terms of the confidence it gives companies to invest, partner or pivot.
His stories emphasize competitive context, spelling out which existing therapies could be displaced, where a new drug might realistically fit and how results could shift negotiating power in future transactions.
Deal-driven view of biopharma strategy
Gardner’s lens on the industry is fundamentally deal-driven, treating licensing agreements, co-development pacts and late-stage trial milestones as strategic moves on a longer board.
He brings out the way R&D decisions, such as backing a risky oncology modality or betting on a partner’s platform, feed directly into business outcomes like portfolio balance and future revenue streams. Rather than covering the science and the strategy in separate tracks, he uses each story to show how they interact: a global trial does not just test a drug, it tests a company’s bet on a partner, a mechanism and a market.
This integrated approach makes his work useful to anyone trying to understand not only what happened in a study or deal, but why it matters for the companies involved and their rivals.
4 more business journalists.
Aaron Karp
Aaron Karp is distinct for connecting airline networks, airport infrastructure, air cargo and policy. He is a senior editor at Air Transport World and has covered aviation since 1999. He has also worked as an editor for cargo-focused and daily aviation publications. His real beat is how airlines and airports respond to growth, regulation, trade conditions, sustainability pressures and technology changes. He covers route planning, network development, airport capacity, infrastructure, cargo flows, trade lanes, safety, air traffic control and future technology. He reports through news, features, opinion pieces, briefings and podcasts. He uses data, executive insight and industry conference reporting to explain market changes. His work links cargo metrics and trade policy to carrier strategy, and connects infrastructure and sustainability decisions to resilience, costs and long-term growth.
Adrienne Roberts
Adrienne Roberts is a business journalist at the Detroit Free Press who covers how policy, regulation and corporate decisions affect Michigan’s cannabis market, jobs, universities and health systems. She has a sustained focus on cannabis taxes, licensing, sales, product rules, consumer safety and local tax revenue. She also reports on unemployment, worker protections, corporate settlements, hiring, higher education, student safety, housing, data centers, health care access and economic forecasts. Roberts joined the Detroit Free Press in 2020 after covering automotive retail, dealers and labor issues for The Wall Street Journal. She explains complex business and regulatory changes with data, legal detail and on-the-ground voices. Her stories focus on practical effects for workers, students, consumers and communities, showing both the numbers and the people behind them.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex DeMarban
Alex DeMarban stands out for tracking major energy projects over time while showing how economic shifts affect local businesses. He reports for the Anchorage Daily News on business, oil and gas, and general assignments. His coverage focuses on Alaska LNG, long-haul energy projects, mining, ports, transportation infrastructure, and the everyday businesses that keep the state running. He examines financing, tax legislation, labor agreements, regulatory approvals, timelines and costs, and connects government and corporate decisions to workers, communities and consumers. He also reports on restaurant closures, grocery stores, breweries, meaderies, parking and trade disputes. His past coverage includes an open-pit mine near the proposed Ambler road, federal port grants and competitive elections. He reports through dollar figures, project details, public records, business owners and affected workers, showing how policy and resource development play out on the ground.